[et_pb_section bb_built=”1″][et_pb_row][et_pb_column type=”4_4″][et_pb_text]

An astonishing one million Americans have Parkinson’s disease, making it the second most common neurodegenerative disorder after Alzheimer’s. This impacts more people than those influenced with other movement disorders like ALS, muscular dystrophy or multiple sclerosis, combined. Characterized by involuntary tremors and debilitating chronic pain, movement disorders are incredibly painful. They impact an individual’s well-being, which makes it hard to interact socially, and the expensive drugs and/or medications can often plummet the patient’s circumstance.

 

The problem is, there’s no known cure for movement disorders. Worse, no one yet knows how to prevent them. Not only do people suffer from them, they also have to rely on treatment approaches with harsh side effects for the remainder of their lives. However, there’s a new treatment in the forefront of movement disorder research, CBD oil. The results are nothing short of miraculous, reducing tremors and lessening pain. CBD is a abbreviation for cannabidiol oil. Created with an extraction process utilizing either the marijuana or hemp plant. Extracting the CBD provides the consumer the amazing medical benefits without the effects of THC. Because there are no psychedelic properties in CBD, studies have demonstrated it is completely safe for consumption. The purpose of the article below is to demonstrate as well as discuss cannabidiol as a promising strategy to treat and prevent movement disorders.

 

Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?

 

Abstract

 

Movement disorders such as Parkinson’s disease and dyskinesia are highly debilitating conditions linked to oxidative stress and neurodegeneration. When available, the pharmacological therapies for these disorders are still mainly symptomatic, do not benefit all patients and induce severe side effects. Cannabidiol is a non-psychotomimetic compound from Cannabis sativa that presents antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective effects. Although the studies that investigate the effects of this compound on movement disorders are surprisingly few, cannabidiol emerges as a promising compound to treat and/or prevent them. Here, we review these clinical and pre-clinical studies and draw attention to the potential of cannabidiol in this field.

 

Keywords: cannabidiol, movement disorders, Parkinson’s disease, Huntington’s disease, dystonic disorders, cannabinoids

 

Cannabidiol (CBD)

 

Cannabidiol (CBD) is one of the over 100 phytocannabinoids identified in Cannabis sativa (ElSohly and Gul, 2014), and constitutes up to 40% of the plant’s extract, being the second most abundant component (Grlic, 1976). CBD was first isolated from marijuana in 1940 by Adams et al. (1940) and its structure was elucidated in 1963 by Mechoulam and Shvo (1963). Ten years later, Perez-Reyes et al. (1973) reported that, unlike the main constituent of cannabis Δ9-tetrahydrocannabinol (Δ9-THC), CBD does not induce psychological effects, leading to the suggestion that CBD was an inactive drug. Nonetheless, subsequent studies demonstrated that CBD modulates the effects of Δ9-THC and displays multiple actions in the central nervous system, including antiepileptic, anxiolytic and antipsychotic effects (Zuardi, 2008).

 

Interestingly, CBD does not induce the cannabinoid tetrad, namely hypomotility, catalepsy, hypothermia, and antinociception. In fact, CBD mitigates the cataleptic effect of Δ9-THC (El-Alfy et al., 2010). Clinical and pre-clinical studies have pointed to beneficial effects of CBD on the treatment of movement disorders. The first studies investigated CBD’s actions on dystonia, with encouraging results. More recently, the studies have been focusing on Parkinson’s (PD) and Huntington’s (HD) diseases. The mechanisms whereby CBD exerts its effects are still not completely understood, mainly because several targets have been identified. Of note, CBD displays anti-inflammatory and antioxidant actions (Campos et al., 2016), and both inflammation and oxidative stress are linked to the pathogenesis of various movement disorders, such as PD (Farooqui and Farooqui, 2011; Niranjan, 2014), HD (Sánchez-López et al., 2012), and tardive dyskinesia (Zhang et al., 2007).

 

It is noteworthy that, when available, the pharmacological treatments for these movement disorders are mainly symptomatic and induce significant side effects (Connolly and Lang, 2014; Lerner et al., 2015; Dickey and La Spada, 2017). Nonetheless, despite its great clinical relevance, the studies evaluating CBD’s role on the pharmacotherapy of movement disorders are surprisingly few. Here, we will review the clinical and pre-clinical evidence and draw attention to the potential of CBD in this field.

 

CBD’s Mechanisms of Action

 

CBD has several molecular targets, and new ones are currently being uncovered. CBD antagonizes the action of CB1 and CB2 receptors agonists, and is suggested to act as an inverse agonist of these receptors (Pertwee, 2008). Moreover, recent evidence point to CBD as a non-competitive negative allosteric modulator of CB1 and CB2 (Laprairie et al., 2015; Martínez-Pinilla et al., 2017). CBD is also an agonist of the vanilloid receptor TRPV1 (Bisogno et al., 2001), and the previous administration of a TRPV1 antagonist blocks some of CBD effects (Long et al., 2006; Hassan et al., 2014). In parallel, CBD inhibits the enzymatic hydrolysis and the uptake of the main endocannabinoid anandamide (Bisogno et al., 2001), an agonist of CB1, CB2 and TRPV1 receptors (Pertwee and Ross, 2002; Ross, 2003). The increase in anandamide levels induced by CBD seems to mediate some of its effects (Leweke et al., 2012). Moreover, in some behavioral paradigms the administration of an inhibitor of anandamide metabolism promotes effects similar to CBD (Pedrazzi et al., 2015; Stern et al., 2017).

 

CBD has also been shown to facilitate the neurotransmission mediated by the serotonin receptor 5-HT1A. It was initially suggested that CBD would act as an agonist of 5-HT1A (Russo et al., 2005), but the latest reports propose that this interaction might be allosteric or through an indirect mechanism (Rock et al., 2012). Although this interaction is not fully elucidated, multiple CBD’s effects were reported to depend on 5-HT1A activation (Espejo-Porras et al., 2013; Gomes et al., 2013; Pazos et al., 2013; Hind et al., 2016; Sartim et al., 2016; Lee et al., 2017).

 

The peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor involved in glucose metabolism and lipid storage, and PPARγ ligands have been reported to display anti-inflammatory actions (O’Sullivan et al., 2009). Data show that CBD can activate this receptor (O’Sullivan et al., 2009), and some of CBD effects are blocked by PPARγ antagonists (Esposito et al., 2011; Dos-Santos-Pereira et al., 2016; Hind et al., 2016). CBD also up-regulates PPARγ in a mice model of multiple sclerosis, an effect suggested to mediate the CBD’s anti-inflammatory actions (Giacoppo et al., 2017b). In a rat model of Alzheimer’s disease, CBD, through interaction with PPARγ, stimulates hippocampal neurogenesis, inhibits reactive gliosis, induces a decline in pro-inflammatory molecules, and consequently inhibits neurodegeneration (Esposito et al., 2011). Moreover, in an in vitro model of the blood-brain barrier, CBD reduces the ischemia-induced increased permeability and VCAM-1 levels—both effects are attenuated by PPARγ antagonism (Hind et al., 2016).

 

CBD also antagonizes the G-protein-coupled receptor GPR55 (Ryberg et al., 2007). GPR55 has been suggested as a novel cannabinoid receptor (Ryberg et al., 2007), but this classification is controversial (Ross, 2009). Currently, the phospholipid lysophosphatidylinositol (LPI) is considered the GPR55 endogenous ligand (Morales and Reggio, 2017). Although only few studies link the CBD effect to its action on GPR55 (Kaplan et al., 2017), it is noteworthy that GPR55 has been associated with PD in an animal model (Celorrio et al., 2017) and with axon growth in vitro (Cherif et al., 2015).

 

More recently, CBD was reported to act as inverse agonist of the G-protein-coupled orphan receptors GPR3, GPR6, and GPR12 (Brown et al., 2017; Laun and Song, 2017). GPR6 has been implicated in both HD and PD. Concerning animal models of PD, GPR6 deficiency was related to both diminished dyskinesia after 6-OHDA lesion (Oeckl et al., 2014), and increased sensitivity to MPTP neurotoxicity (Oeckl and Ferger, 2016). Moreover, Hodges et al. (2006) described decreased expression of GPR6 in brain of HD patients, compared to control. GPR3 is suggested as a biomarker for the prognosis of multiple sclerosis (Hecker et al., 2011). In addition, GPR3, GPR6, and GPR12 have been implicated in cell survival and neurite outgrow (Morales et al., 2018).

 

CBD has also been reported to act on mitochondria. Chronic and acute CBD administration increases the activity of mitochondrial complexes (I, II, II-III, and IV), and of creatine kinase in the brain of rats (Valvassori et al., 2013). In a rodent model of iron overload—that induces pathological changes that resemble neurodegenerative disorders—CBD reverses the iron-induced epigenetic modification of mitochondrial DNA and the reduction of succinate dehydrogenase’s activity (da Silva et al., 2018). Of note, multiple studies associate mitochondrial dysfunctions with the pathophysiology of PD (Ammal Kaidery and Thomas, 2018).

 

In parallel, several studies show anti-inflammatory and antioxidant actions of CBD (Campos et al., 2016). CBD treatment decreases the levels of the pro-inflammatory cytokines IL-1β, TNF-α, IFN-β, IFN-γ, IL-17, and IL-6 (Watzl et al., 1991; Weiss et al., 2006; Esposito et al., 2007, 2011; Kozela et al., 2010; Chen et al., 2016; Rajan et al., 2016; Giacoppo et al., 2017b), and increases the levels of the anti-inflammatory cytokines IL-4 and IL-10 (Weiss et al., 2006; Rajan et al., 2016). In addition, it inhibits the expression of iNOS (Esposito et al., 2007; Pan et al., 2009; Chen et al., 2016; Rajan et al., 2016) and COX-2 (Chen et al., 2016) induced by distinct mechanisms. CBD also displays antioxidant properties, being able to donate electrons under a variable voltage potential and to prevent the hydroperoxide-induced oxidative damage (Hampson et al., 1998). In rodent models of PD and HD, CBD up-regulates the mRNA levels of the antioxidant enzyme superoxide dismutase (Garcia-Arencibia et al., 2007; Sagredo et al., 2007). In accordance, CBD decreases oxidative parameters in in vitro models of neurotoxicity (Hampson et al., 1998; Iuvone et al., 2004; Mecha et al., 2012). Of note, the anti-inflammatory and antioxidant effects of CBD on lipopolysaccharide-stimulated murine macrophages are suppressed by a TRPV1 antagonist (Rajan et al., 2016). It has also been shown that CBD can affect the expression of several genes involved in zinc homeostasis, which is suggested to be linked to its anti-inflammatory and antioxidant actions (Juknat et al., 2012).

 

CBD’s mechanisms of action are summarized in Figure ​1.

 

 

Parkinson’s Disease (PD)

 

PD is among the most common neurodegenerative disorders, with a prevalence that increases with age, affecting 1% of the population over 60 years old (Tysnes and Storstein, 2017). The disease is characterized by motor impairment (hypokinesia, tremors, muscle rigidity) and non-motor symptoms (e.g., sleep disturbances, cognitive deficits, anxiety, depression, psychotic symptoms) (Klockgether, 2004).

 

The pathophysiology of PD is mainly associated with the loss of midbrain dopaminergic neurons in the substantia nigra pars compacta (SNpc), with consequent reduced levels of dopamine in the striatum (Dauer and Przedborski, 2003). When the motor symptoms appear, about 60% of dopaminergic neurons is already lost (Dauer and Przedborski, 2003), hindering a possible early diagnosis. The most effective and used treatment for PD is L-DOPA, a precursor of dopamine that promotes an increase in the level of dopamine in the striatum, improving the motor symptoms (Connolly and Lang, 2014). However, after a long-term treatment the effect of L-DOPA can be unstable, presenting fluctuations in symptoms improvement (on / off effect) (Jankovic, 2005; Connolly and Lang, 2014). In addition, involuntary movements (namely L-DOPA-induced dyskinesia) appear in approximately 50% of the patients (Jankovic, 2005).

 

The first study with CBD on PD patients aimed to verify CBD’s effects on the psychotic symptoms. Treatment with CBD for 4 weeks decreased the psychotic symptoms, evaluated by the Brief Psychiatric Rating Scale and the Parkinson Psychosis Questionnaire, without worsening the motor function or inducing adverse effects (Zuardi et al., 2009). Later, in a case series with four PD patients, it was verified that CBD is able to reduce the frequency of the events related to REM sleep behavior disorder (Chagas et al., 2014a). In addition, although not ameliorating PD patients’ motor function or their general symptoms score, treatment with CBD for 6 weeks improves PD’s patients quality of life (Chagas et al., 2014b). The authors suggest that this effect might be related to CBD’s anxiolytic, antidepressant and antipsychotic properties (Chagas et al., 2014b).

 

Although the studies with patients with PD report beneficial effects of CBD only on the non-motor symptoms, CBD has been shown to prevent and/or reverse increased catalepsy behavior in rodents. When administered before the cataleptic agents haloperidol (antipsychotic drug), L-nitro-N-arginine (non-selective inhibitor of nitric oxide synthase) or WIN 55-212,2 (agonist of cannabinoid receptors), CBD hinders the cataleptic behavior in a dose-dependent manner (Gomes et al., 2013). A possible role of the activation of serotonin receptors 5-HT1A in this action has been proposed, because this effect of CBD is blocked by the pre-treatment with the 5-HT1A antagonist WAY100635 (Gomes et al., 2013). In accordance, Sonego et al. (2016) showed that CBD diminishes the haloperidol-induced catalepsy and c-Fos protein expression in the dorsal striatum, also by a mechanism dependent on 5-HT1A activation. Moreover, CBD prevents the increased catalepsy behavior induced by repeated administration of reserpine (Peres et al., 2016).

 

In addition, pre-clinical studies in animal models of PD have shown neuroprotective effects of CBD. The unilateral injection of the toxin 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle promotes neurodegeneration of nigrostriatal dopaminergic neurons, being used to model PD (Bové et al., 2005). When inside the cell, the neurotoxin 6-OHDA oxidizes in hydrogen peroxide and paraquinone, causing death mainly of catecolaminergic neurons (Breese and Traylor, 1971; Bové et al., 2005). This neurodegeneration leads to depletion of dopamine and decrease in tyrosine hydroxylase activity in caudate-putamen (Bové et al., 2005; Lastres-Becker et al., 2005). Treatment with CBD during the 2 weeks following 6-OHDA administration prevents these effects (Lastres-Becker et al., 2005). In another study, it was observed that CBD’s protective effects after 6-OHDA injury are accompanied by elevation of mRNA levels of the antioxidant enzyme Cu,Zn-superoxide dismutase in substantia nigra (Garcia-Arencibia et al., 2007). The protective effects of CBD in this model do not seem to depend on the activation of CB1 receptors (Garcia-Arencibia et al., 2007). In addition to preventing the loss of dopaminergic neurons—assessed by tyrosine hydroxylase immunostaining –, the administration of CBD after 6-OHDA injury attenuates the activation of microglia in substantia nigra (Garcia et al., 2011).

 

In an in vitro study, CBD increased the viability of cells treated with the neurotoxin N-methyl-4-phenylpyrimidine (MPP+), and prevented the MPP+-induced increase in caspase-3 activation and decrease in levels of nerve growth factor (NGF) (Santos et al., 2015). CBD treatment was also able to induce cell differentiation even in the presence of MPP+, an effect that depends on trkA receptors (Santos et al., 2015). MPP+ is a product of oxidation of MPTP that inhibits complex I of the respiratory chain in dopaminergic neurons, causing a rapid neuronal death (Schapira et al., 1990; Meredith et al., 2008).

 

Data from clinical and pre-clinical studies are summarized in Tables ​1, ​2, respectively.

 

 

 

Huntington’s Disease (HD)

 

HD is a fatal progressive neurodegenerative disease characterized by motor dysfunctions, cognitive loss and psychiatric manifestations (McColgan and Tabrizi, 2018). HD is caused by the inclusion of trinucleotides (CAG) in the exons of the huntingtin gene, on chromosome 4 (MacDonald et al., 1993; McColgan and Tabrizi, 2018), and its prevalence is 1–10,000 (McColgan and Tabrizi, 2018). Neurodegeneration in HD affects mainly the striatal region (caudate and putamen) and this neuronal loss is responsible for the motor symptoms (McColgan and Tabrizi, 2018). Cortical degeneration is seen in later stages, and huntingtin inclusions are seen in few cells, but in all patients with HD (Crook and Housman, 2011). The diagnosis of HD is based on motor signs accompanied by genetic evidence, which is positive genetic test for the expansion of the huntingtin gene or family history (Mason and Barker, 2016; McColgan and Tabrizi, 2018).

 

The pharmacotherapy of HD is still directed toward the symptomatic relief of the disease, i.e., the motor disorders believed to be due to dopaminergic hyperactivity. This treatment is often conducted with typical and atypical antipsychotics, but in some cases the use of dopaminergic agonists is needed (Mason and Barker, 2016; McColgan and Tabrizi, 2018). Indeed, the role of dopamine in HD is not fully elucidated yet. Regarding the cognitive deficits, none of the investigated drugs was able to promote improvements (Mason and Barker, 2016; McColgan and Tabrizi, 2018).

 

Recently, there has been a growing number of studies aiming to verify the therapeutic potential of cannabinoid compounds in the treatment of HD, mainly because some cannabinoids present hypokinetic characteristics (Lastres-Becker et al., 2002). In a controlled clinical trial, patients with HD were treated with CBD for 6 weeks. There was no significant reduction in the chorea indicators, but no toxicity was observed (Consroe et al., 1991).

 

The protective effects of CBD and other cannabinoids were also evaluated in a cell culture model of HD, with cells expressing mutated huntingtin. In this model, the induction of huntingtin promotes rapid and extensive cell death (Aiken et al., 2004). CBD and the other three cannabinoid compounds tested—Δ8-THC, Δ9-THC, and cannabinol—show 51–84% protection against the huntingtin-induced cell death (Aiken et al., 2004). These effects seem to be independent of CB1 activation, since absence of CB1 receptors has been reported in PC12, the cell line used (Molderings et al., 2002). The authors suggest that the cannabinoids exert this protective effect by antioxidant mechanisms (Aiken et al., 2004).

 

Regarding studies with animal models, treatment with 3-nitropropionic acid (3-NP), an inhibitor of complex II of the respiratory chain, induces striatal damage—mainly by calpain activation and oxidative injury –, being suggested as relevant to study HD (Brouillet et al., 2005). Sub-chronic administration of 3-NP in rats reduces GABA contents and the levels of mRNA for several markers of striatal GABAergic neurons projections (Sagredo et al., 2007). In addition, 3-NP diminishes the levels of mRNA for the antioxidant enzymes superoxide dismutase-1 (SOD-1) and -2 (SOD-2) (Sagredo et al., 2007). The administration of CBD reverses or attenuates these 3-NP-induced alterations (Sagredo et al., 2007). CBD’s neuroprotective effects are not blocked by the administration of antagonists of the CB1, TRPV1 or A2A receptors (Sagredo et al., 2007).

 

More recently, clinical and pre-clinical HD studies started to investigate the effects of Sativex® (CBD in combination with Δ9-THC in an approximately 1:1 ratio). In accordance with what previously seen with CBD alone, Sativex administration attenuates all the 3-NP induced neurochemical, histological and molecular alterations (Sagredo et al., 2011). These effects do not seem to be linked to activation of CB1 or CB2 receptors (Sagredo et al., 2011). Authors also observed a protective effect of Sativex in reducing the increased expression of iNOS gene induced by malonate (Sagredo et al., 2011). Malonate administration leads to striatal damage by apoptosis and inflammatory events related to glial activation, being used as an acute model for HD (Sagredo et al., 2011; Valdeolivas et al., 2012).

 

In a subsequent study, it was observed that the administration of a Sativex-like combination attenuates all the malonate-induced alterations, namely: increased edema, decreased number of surviving cells, enhanced number of degenerating cells, strong glial activation, and increased expression of inflammatory markers (iNOS and IGF-1) (Valdeolivas et al., 2012). Although the beneficial effects of Sativex on cell survival are blocked by both CB1 or CB2 antagonists, CB2 receptors seem to have a greater role in the protective effect observed (Valdeolivas et al., 2012).

 

The beneficial effects of Sativex have also been described in the R6/2 mice, a transgenic model of HD. Treatment with a Sativex-like combination, although not reversing animal’s deterioration in rotarod performance, attenuates the elevated clasping behavior, that reflects dystonia (Valdeolivas et al., 2017). Moreover, treatment mitigates R6/2 mice reduced metabolic activity in basal ganglia and some of the alterations in markers of brain integrity (Valdeolivas et al., 2017).

 

In spite of the pre-clinical encouraging results with Sativex, a pilot trial with 25 HD patients treated with Sativex for 12 weeks failed to detect improvement in symptoms or molecular changes on biomarkers (López-Sendón Moreno et al., 2016). Nonetheless, Sativex did not induce severe adverse effects or clinical worsening (López-Sendón Moreno et al., 2016). The authors suggest that future studies, with higher doses and/or longer treatment periods, are in need. More recently, one study described the results of administering cannabinoid drugs to 7 patients (2 of them were treated with Sativex; the others received dronabinol or nabilone, agonists of the cannabinoid receptors): patients displayed improvement on UHDRS motor score and dystonia subscore (Saft et al., 2018).

 

Tables ​1, ​2 summarize data from clinical and pre-clinical studies, respectively.

 

Dr. Alex Jimenez’s Insight

Involuntary muscle spasms, tremors and jerking are all uncontrollable movements known as dyskinesia, which are the most common symptoms of a variety of movement disorders. Movement disorders often have no known cause and these are considered to have no cure. As a result, individuals with these debilitating conditions have to turn to drugs and/or medications to keep their symptoms under control for the rest of their lives. However, several research studies have been conducted to determine the effectiveness of CBD, or cannabidiol, for the treatment and prevention of movement disorders. In one study, CBD was found to decrease pain and reduce inflammation in patients with Parkinson’s disease without the psychoactive effects of THC. Moreover, healthcare professionals and researchers alike are trying to demonstrate further health benefits of CBD on movement disorders.

 

Other Movement Disorders

 

Dystonias are the result of abnormal muscles tone, causing involuntary muscle contraction, and resulting in repetitive movements or abnormal posture (Breakefield et al., 2008). Dystonias can be primary, for instance paroxysmal dyskinesia, or secondary to other conditions or drug use, such as tardive dyskinesia after prolonged treatment with antipsychotic drugs (Breakefield et al., 2008).

 

Consroe et al. (1986) were the first to evaluate the effects of CBD alone in movement disorders. In this open label study, the five patients with dystonic movement disorders displayed 20–50% improvement of dystonic symptoms when treated with CBD for 6 weeks. Of note, two patients with simultaneous PD’s signs showed worsening of their hypokinesia and/or resting tremor when receiving the higher doses of CBD. However, it should be noted that in two more recent studies with PD patients no worsening of motor function was seen (Zuardi et al., 2009; Chagas et al., 2014b). In accordance, Sandyk et al. (1986) reported improvement of dystonic symptoms in two patients—one with idiopathic spasmodic torticollis and one with generalized torsion dystonia—after acute treatment with CBD.

 

The effects of CBD on dystonic movements were also evaluated in pre-clinical studies. In a hamster model of idiopathic paroxysmal dystonia, the higher dose of CBD showed a trend to delay the progression of dystonia (Richter and Loscher, 2002). In addition, CBD prevents the increase in vacuous chewing movements, i.e., dyskinesia, promoted by repeated administration of reserpine (Peres et al., 2016). CBD’s beneficial effects are also seen in L-DOPA-induced dyskinesia in rodents, but only when CBD is administered with capsazepine, an antagonist of TRPV1 receptors (Dos-Santos-Pereira et al., 2016). These effects seem to depend on CB1 and PPARγ receptors (Dos-Santos-Pereira et al., 2016). In addition, treatment with capsazepine and CBD decreases the expression of inflammatory markers, reinforcing the suggestion that the anti-inflammatory actions of CBD may be beneficial to the treatment of dyskinesia (Dos-Santos-Pereira et al., 2016).

 

Moreover, Sativex has been used in the treatment of spasticity in multiple sclerosis. Spasticity is a symptom that affects up to 80% of patients with multiple sclerosis and is associated with poorer quality of life (Flachenecker et al., 2014). A significant portion of patients does not respond to the conventional anti-spasmodic therapies, and some strategies are invasive, posing risks of complications (Flachenecker et al., 2014; Crabtree-Hartman, 2018). Recent data point to Sativex as a valid and well-tolerated therapeutic option. Sativex is able to treat the spasms, improving the quality of life, and displays a low incidence of adverse effects (Giacoppo et al., 2017a).

 

Data from clinical and pre-clinical studies are summarized in Tables ​1, 2, respectively.

 

Safety and Side Effects

 

One important concern is whether CBD is a safe therapeutic strategy. Several preclinical and clinical reports show that CBD does not alter metabolic and physiological parameters, such as glycemia, prolactin levels, blood pressure, and heart rate. In addition, CBD does not modify hematocrit, leukocyte and erythrocyte counts, and blood levels of bilirubin and creatinine in humans. CBD also does not affect urine osmolarity, pH, albumin levels, and leukocyte and erythrocyte counts. Moreover, in vitro studies demonstrate that CBD does not alter embryonic development nor the vitality of non-tumor cell lines. The most reported side effects of CBD are tiredness, diarrhea, and changes on appetite. CBD does not seem to induce tolerance. For a broad review of CBD’s side effects, see Bergamaschi et al. (2011) and Iffland and Grotenhermen (2017).

 

In the context of movement disorders with concomitant cognitive symptoms, as the ones discussed here, it is crucial to evaluate the potential motor and cognitive side effects of CBD. CBD does not induce catalepsy behavior in rodents—being even able to attenuate the effects of several cataleptic agents, as discussed above (El-Alfy et al., 2010; Gomes et al., 2013; Peres et al., 2016; Sonego et al., 2016). In accordance, CBD does not induce extrapyramidal effects in humans (Leweke et al., 2012).

 

With respect to cognitive effects, studies report that CBD does not impair cognition, being even able to improve it in some conditions. Pre-clinical data show that CBD restores the deficit in the novel object recognition task in mice treated with MK-801 (a protocol used to model schizophrenia) (Gomes et al., 2015), in rats submitted to neonatal iron overload (Fagherazzi et al., 2012), in a transgenic mice model for Alzheimer’s disease (Cheng et al., 2014), and in a mice model for cerebral malaria (Campos et al., 2015). CBD also reverses impaired social recognition in a murine model for Alzheimer’s disease (Cheng et al., 2014) and restores the deficits in the Morris water maze—a task that evaluates spatial learning—in rodent models for Alzheimer’s disease (Martín-Moreno et al., 2011), brain ischemia (Schiavon et al., 2014) and cerebral malaria (Campos et al., 2015). In addition, studies demonstrate that CBD per se does not modify animals’ performance in cognitive tasks (Osborne et al., 2017; Myers et al., 2018) and does not induce withdrawal after prolonged treatment (Myers et al., 2018). In accordance, in one recent clinical trial using CBD as an adjunctive therapy for schizophrenia, CBD group displayed greater cognitive improvement (assessed by BACS—Brief Assessment of Cognition in Schizophrenia), although it fell short of significance (McGuire et al., 2018). CBD also improves facial emotion recognition in cannabis users (Hindocha et al., 2015).

 

It is noteworthy that in some cases, particularly concerning multiple sclerosis and HD clinical studies, CBD per se does not seem to be beneficial. However, when CBD is administered with Δ9-THC in a 1:1 ratio, therapeutic effects are observed. Therefore, it is also important to evaluate the interactions between CBD and Δ9-THC as well as the adverse effects of this mixture. Multiple reports point to deleterious effects of Δ9-THC on human cognition, mainly on memory and emotional processing (Colizzi and Bhattacharyya, 2017). On the other hand, studies reveal that CBD can counteract Δ9-THC detrimental cognitive effects in rodents and monkeys (Wright et al., 2013; Jacobs et al., 2016; Murphy et al., 2017). Nonetheless, this protective effect depends on the doses, on the interval between CBD and Δ9-THC administration, as well as on the behavioral paradigm used. In fact, some pre-clinical studies do not observe the protective effect of CBD against the Δ9-THC cognitive effects (Wright et al., 2013; Jacobs et al., 2016) or even show that CBD may potentiate them (Hayakawa et al., 2008). Limited clinical evidence indicate that CBD does not worse Δ9-THC cognitive effects and, depending on the dose, may protect against them (Colizzi and Bhattacharyya, 2017; Englund et al., 2017; Osborne et al., 2017). Multiple clinical studies with Sativex have not observed motor or cognitive adverse effects (Aragona et al., 2009; Rekand, 2014; López-Sendón Moreno et al., 2016; Russo et al., 2016). Nevertheless, one recent open-label study compared multiple sclerosis patients who continued the treatment with Sativex to those who quitted and reported worse balance and decrease in cognitive performance in the continuers (Castelli et al., 2018). In line with these findings, in an observational study with a large population of Italian patients with multiple sclerosis, cognitive/psychiatric disturbances were seen in 3.9% of the cases (Patti et al., 2016).

 

Conclusions

 

The data reviewed here point to a protective role of CBD in the treatment and/or prevention of some movement disorders. Although the studies are scarce, CBD seems to be effective on treating dystonic movements, both primary and secondary. It is noteworthy that in some cases, particularly concerning multiple sclerosis and HD, the clinical beneficial effects are observed only when CBD is combined with Δ9-THC in a 1:1 ratio (Sativex). In fact, these therapeutic effects are probably due to Δ9-THC, since they are also seen with other cannabinoid agonists (Curtis et al., 2009; Nielsen et al., 2018; Saft et al., 2018). Nonetheless, CBD is shown to diminish the Δ9-THC unwanted effects, such as sedation, memory impairments, and psychosis (Russo and Guy, 2006). Data regarding HD are scarce, but the results of using Sativex in multiple sclerosis are encouraging. Reviews of the clinical use of this compound in the last decade point to effectiveness in the treatment of spasticity as well as improvement in quality of life, with low incidence of adverse effects (Giacoppo et al., 2017a).

 

In respect to PD, although the pre-clinical studies are promising, the few studies with patients failed to detect improvement of the motor symptoms after treatment with CBD. There is a significant difference between the clinical and pre-clinical PD studies. In animals, the beneficial effects are seen when CBD is administered prior to or immediately after the manipulation that induces the PD-like symptoms. Of note, when treatment with CBD commences 1 week after the lesion with 6-OHDA, the protective effects are not seen (Garcia-Arencibia et al., 2007). These data suggest that CBD’s might have a preventive role rather than a therapeutic one in PD. In clinical practice, PD is diagnosed subsequently to the emergence of motor symptoms—that appear up to 10 years after the beginning of neurodegeneration and the onset of non-motor symptoms (Schrag et al., 2015). When the diagnosis occur, approximately 60% of the dopaminergic neurons has already been lost (Dauer and Przedborski, 2003). The fact that in clinical trials CBD is administered only after this substantial progression of the disease might explain the conflicting results. Unfortunately, the early diagnosis of PD remains a challenge, posing difficulty to the implementation of preventive strategies. The development of diagnosis criteria able to detect PD in early stages would probably expand the CBD’s applications in this disease.

 

The molecular mechanisms associated with CBD’s improvement of motor disorders are likely multifaceted. Data show that it might depend on CBD’s actions on 5-HT1A, CB1, CB2, and/or PPARγ receptors. Moreover, all movement disorders are in some extent linked to oxidative stress and inflammation, and CBD has been reported to display an antioxidant and anti-inflammatory profile, in vitro and in animal models for movement abnormalities.

 

The studies investigating the role of CBD on the treatment of movement disorders are few. Furthermore, differences in the dose and duration of treatment as well as in the stage of the disease (for instance, PD patients are treated only in an advanced stage of the disease) among these studies (shown in detail in Table ​Table1)1) limit the generalization of the positive effect of CBD and might explain the conflicting results. Notwithstanding, the beneficial neuroprotective profile of CBD added to the preliminary results described here are encouraging. Undoubtedly, future investigations are needed to endorse these initial data and to elucidate the mechanisms involved in the preventive and/or therapeutic potential of CBD on movement disorders.

 

Introduction to the Endocannabinoid System

 

Since you read the article concerning the effects of cannabidiol on movement disorders, one thing will become quickly evident: cannabis has a profound influence on the human body. This one herb and its own variety of therapeutic chemicals seem to impact every aspect of the brain and body. However, how is this possible? There’s a system in the human body which many individuals are not aware of nor do they known how important it’s functions are: the endocannabinoid system.

 

What Is The Endocannabinoid System?

 

The endogenous cannabinoid system, or the cannabinoid system, named after the plant that resulted in its discovery, is possibly the most important physiologic system involved in establishing and maintaining human health. Endocannabinoids and their receptors are found throughout the body: in the brain, organs, connective tissues, glands, and immune cells. In each tissue, the endocannabinoid system performs various tasks, but the goal is always the same: homeostasis, the maintenance of a stable internal environment despite changes in the external environment.

 

Cannabinoids promote homeostasis at every level of biological lifetime, from the sub-cellular, into the organism, and possibly into the community and more. Here is one instance: autophagy, a process where a cell sequesters part of its contents to be self-digested and recycled, is mediated by the endocannabinoid system. While this procedure keeps normal cells alive, permitting them to maintain a balance between the synthesis, degradation, and subsequent recycling of cellular products, it has a fatal effect on cancerous tumor cells, causing them to consume themselves at a programmed cellular suicide. The death of cancer cells, of course, promotes homeostasis and survival in the level of the whole organism.

 

Endocannabinoids and cannabinoids are also found at the intersection of the body’s various systems, enabling communication and coordination between distinct cell types. In the case of an injury, for instance, cannabinoids are available diminishing the discharge of activators and sensitizers in the injured tissue, stabilizing the nerve cell to stop excessive firing, and calming nearby immune cells to prevent discharge of pro-inflammatory substances. Three different mechanisms of action on three distinct cell types for one purpose: minimize the pain and damage caused by the injury.

 

The endocannabinoid system, using its complicated activities in our immune system, nervous system, and all of the body’s organs, is literally a bridge between the brain and the body. By understanding this system we begin to observe a mechanism that explains the way the states of awareness can promote disease or health.

 

Along with regulating the human body’s internal and cellular homeostasis, cannabinoids affect an individual’s connection with the external environment. Socially, the management of cannabinoids clearly changes human behavior, frequently promoting sharing, comedy, and imagination. By mediating neurogenesis, neuronal plasticity, and learning, cannabinoids may directly affect a person’s open-mindedness and capability to move beyond limiting patterns of thought and behaviour from past scenarios. Reformatting these older patterns is an essential part of health in our quickly changing environment. Furthermore, the article above found that CBD appears to be an effective treatment option for dystonic movements, both primary and secondary, although further reasearch studies are required. The research of CBD has been controversial, however, more and more studies are starting to demonstrate the health benefits of cannabidiol. Information referenced from the National Center for Biotechnology Information (NCBI). The scope of our information is limited to chiropractic as well as to spinal injuries and conditions. To discuss the subject matter, please feel free to ask Dr. Jimenez or contact us at 915-850-0900 .

 

Curated by Dr. Alex Jimenez

Additional Topics: Back Pain

Back pain is one of the most prevalent causes for disability and missed days at work worldwide. As a matter of fact, back pain has been attributed as the second most common reason for doctor office visits, outnumbered only by upper-respiratory infections. Approximately 80 percent of the population will experience some type of back pain at least once throughout their life. The spine is a complex structure made up of bones, joints, ligaments and muscles, among other soft tissues. Because of this, injuries and/or aggravated conditions, such as herniated discs, can eventually lead to symptoms of back pain. Sports injuries or automobile accident injuries are often the most frequent cause of back pain, however, sometimes the simplest of movements can have painful results. Fortunately, alternative treatment options, such as chiropractic care, can help ease back pain through the use of spinal adjustments and manual manipulations, ultimately improving pain relief.

 

 

 

EXTRA IMPORTANT TOPIC: Lower Back Pain Management

 

MORE TOPICS: EXTRA EXTRA: Chronic Pain Care Center

 

 

[/et_pb_text][et_pb_accordion _builder_version=”3.10″][et_pb_accordion_item _builder_version=”3.10″ title=”Blank” use_background_color_gradient=”off” background_color_gradient_start=”#2b87da” background_color_gradient_end=”#29c4a9″ background_color_gradient_type=”linear” background_color_gradient_direction=”180deg” background_color_gradient_direction_radial=”center” background_color_gradient_start_position=”0%” background_color_gradient_end_position=”100%” background_color_gradient_overlays_image=”off” parallax=”off” parallax_method=”on” background_size=”cover” background_position=”center” background_repeat=”no-repeat” background_blend=”normal” allow_player_pause=”off” background_video_pause_outside_viewport=”on” text_shadow_style=”none” box_shadow_style=”none” custom_css_main_element=”display:none;” /][et_pb_accordion_item _builder_version=”3.10″ title=”References” use_background_color_gradient=”off” background_color_gradient_start=”#2b87da” background_color_gradient_end=”#29c4a9″ background_color_gradient_type=”linear” background_color_gradient_direction=”180deg” background_color_gradient_direction_radial=”center” background_color_gradient_start_position=”0%” background_color_gradient_end_position=”100%” background_color_gradient_overlays_image=”off” parallax=”off” parallax_method=”on” background_size=”cover” background_position=”center” background_repeat=”no-repeat” background_blend=”normal” allow_player_pause=”off” background_video_pause_outside_viewport=”on” text_shadow_style=”none” box_shadow_style=”none”]

1. Adams R., Hunt M., Clark J. (1940). Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. I. J. Am. Chem. Soc. 62, 196–200. 10.1021/ja01858a058 [Cross Ref]
2. Aiken C. T., Tobin A. J., Schweitzer E. S. (2004). A cell-based screen for drugs to treat Huntington’s disease. Neurobiol. Dis. 16, 546–555. 10.1016/j.nbd.2004.04.001 [PubMed] [Cross Ref]
3. Ammal Kaidery N., Thomas B. (2018). Current perspective of mitochondrial biology in Parkinson’s disease. Neurochem. Int. [Epub ahead of print]. 10.1016/j.neuint.2018.03.001 [PMC free article][PubMed] [Cross Ref]
4. Aragona M., Onesti E., Tomassini V., Conte A., Gupta S., Gilio F., et al. . (2009). Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin. Neuropharmacol. 32, 41–47. 10.1097/WNF.0B013E3181633497[PubMed] [Cross Ref]
5. Bergamaschi M. M., Queiroz R. H., Zuardi A. W., Crippa J. A. (2011). Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr. Drug Saf. 6, 237–249. 10.2174/157488611798280924 [PubMed] [Cross Ref]
6. Bisogno T., Hanus L., De Petrocellis L., Tchilibon S., Ponde D. E., Brandi I., et al. . (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134, 845–852. 10.1038/sj.bjp.0704327 [PMC free article] [PubMed] [Cross Ref]
7. Bové J., Prou D., Perier C., Przedborski S. (2005). Toxin-induced models of Parkinson’s disease. NeuroRx 2, 484–494. 10.1602/neurorx.2.3.484 [PMC free article] [PubMed] [Cross Ref]
8. Breakefield X. O., Blood A. J., Li Y., Hallett M., Hanson P. I., Standaert D. G. (2008). The pathophysiological basis of dystonias. Nat. Rev. Neurosci. 9, 222–234. 10.1038/nrn2337 [PubMed][Cross Ref]
9. Breese G. R., Traylor T. D. (1971). Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine. Br. J. Pharmacol. 42, 88–99. 10.1111/j.1476-5381.1971.tb07089.x [PMC free article] [PubMed] [Cross Ref]
10. Brouillet E., Jacquard C., Bizat N., Blum D. (2005). 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington’s disease. J. Neurochem. 95, 1521–1540. 10.1111/j.1471-4159.2005.03515.x [PubMed] [Cross Ref]
11. Brown K. J., Laun A. S., Song Z. H. (2017). Cannabidiol, a novel inverse agonist for GPR12. Biochem. Biophys. Res. Commun. 493, 451–454. 10.1016/j.bbrc.2017.09.001 [PMC free article][PubMed] [Cross Ref]
12. Campos A. C., Brant F., Miranda A. S., Machado F. S., Teixeira A. L. (2015). Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria. Neuroscience 289, 166–180. 10.1016/j.neuroscience.2014.12.051 [PubMed] [Cross Ref]
13. Campos A. C., Fogaca M. V., Sonego A. B., Guimaraes F. S. (2016). Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol. Res. 112, 119–127. 10.1016/j.phrs.2016.01.033[PubMed] [Cross Ref]
14. Castelli L., Prosperini L., Pozzilli C. (2018). Balance worsening associated with nabiximols in multiple sclerosis. Mult. Scler. J. [Epub ahead of print]. 10.1177/1352458518765649 [PubMed][Cross Ref]
15. Celorrio M., Rojo-Bustamante E., Fernandez-Suarez D., Saez E., Estella-Hermoso de Mendoza A., Muller C. E., et al. . (2017). GPR55: a therapeutic target for Parkinson’s disease?Neuropharmacology 125, 319–332. 10.1016/j.neuropharm.2017.08.017 [PubMed] [Cross Ref]
16. Chagas M. H., Eckeli A. L., Zuardi A. W., Pena-Pereira M. A., Sobreira-Neto M. A., Sobreira E. T., et al. . (2014a). Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. J. Clin. Pharm. Ther. 39, 564–566. 10.1111/jcpt.12179 [PubMed] [Cross Ref]
17. Chagas M. H., Zuardi A. W., Tumas V., Pena-Pereira M. A., Sobreira E. T., Bergamaschi M. M., et al. . (2014b). Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. J. Psychopharmacol. 28, 1088–1098. 10.1177/0269881114550355[PubMed] [Cross Ref]
18. Chen J., Hou C., Chen X., Wang D., Yang P., He X., et al. (2016). Protective effect of cannabidiol on hydrogen peroxide induced apoptosis, inflammation and oxidative stress in nucleus pulposus cells. Mol. Med. Rep. 14, 2321–2327. 10.3892/mmr.2016.5513 [PubMed] [Cross Ref]
19. Cheng D., Low J. K., Logge W., Garner B., Karl T. (2014). Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1E9 mice. Psychopharmacology 231, 3009–3017. 10.1007/s00213-014-3478-5 [PubMed] [Cross Ref]
20. Cherif H., Argaw A., Cecyre B., Bouchard A., Gagnon J., Javadi P., et al. . (2015). Role of GPR55 during axon growth and target innervation. eNeuro 2:ENEURO.0011-15.2015. 10.1523/ENEURO.0011-15.2015 [PMC free article] [PubMed] [Cross Ref]
21. Colizzi M., Bhattacharyya S. (2017). Does cannabis composition matter? differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition. Curr. Addict. Rep. 4, 62–74. 10.1007/s40429-017-0142-2 [PMC free article] [PubMed] [Cross Ref]
22. Connolly B. S., Lang A. E. (2014). Pharmacological treatment of Parkinson disease: a review. JAMA 311, 1670–1683. 10.1001/jama.2014.3654 [PubMed] [Cross Ref]
23. Consroe P., Laguna J., Allender J., Snider S., Stern L., Sandyk R., et al. . (1991). Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol. Biochem. Behav. 40, 701–708. 10.1016/0091-3057(91)90386-G [PubMed] [Cross Ref]
24. Consroe P., Sandyk R., Snider S. R. (1986). Open label evaluation of cannabidiol in dystonic movement disorders. Int. J. Neurosci. 30, 277–282. 10.3109/00207458608985678 [PubMed][Cross Ref]
25. Crabtree-Hartman E. (2018). Advanced symptom management in multiple sclerosis. Neurol. Clin.36, 197–218. 10.1016/j.ncl.2017.08.015 [PubMed] [Cross Ref]
26. Crook Z. R., Housman D. (2011). Huntington’s disease: can mice lead the way to treatment? Neuron69, 423–435. 10.1016/j.neuron.2010.12.035 [PMC free article] [PubMed] [Cross Ref]
27. Curtis A., Mitchell I., Patel S., Ives N., Rickards H. (2009). A pilot study using nabilone for symptomatic treatment in Huntington’s disease. Mov. Disord. 24, 2254–2259. 10.1002/mds.22809[PubMed] [Cross Ref]
28. da Silva V. K., de Freitas B. S., Dornelles V. C., Kist L. W., Bogo M. R., Silva M. C., et al. . (2018). Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: reversal by cannabidiol. Brain Res. Bull. 139, 1–8. 10.1016/j.brainresbull.2018.01.014 [PubMed] [Cross Ref]
29. Dauer W., Przedborski S. (2003). Parkinson’s disease: mechanisms and models. Neuron 39, 889–909. 10.1016/S0896-6273(03)00568-3 [PubMed] [Cross Ref]
30. Dickey A. S., La Spada A. R. (2017). Therapy development in Huntington disease: from current strategies to emerging opportunities. Am. J. Med. Genet. A 176, 842–861. 10.1002/ajmg.a.38494 [PMC free article] [PubMed] [Cross Ref]
31. Dos-Santos-Pereira M., da-Silva C. A., Guimaraes F. S., Del-Bel E. (2016). Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: possible mechanism of action. Neurobiol. Dis. 94, 179–195. 10.1016/j.nbd.2016.06.013 [PubMed] [Cross Ref]
32. El-Alfy A. T., Ivey K., Robinson K., Ahmed S., Radwan M., Slade D., et al. . (2010). Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol. Biochem. Behav. 95, 434–442. 10.1016/j.pbb.2010.03.004 [PMC free article] [PubMed] [Cross Ref]
33. ElSohly M., Gul W. (2014). Constituents of Cannabis sativa, in Handbook of Cannabis, ed Pertwee R. G., editor. (New York, NY: Oxford University Press; ), 1093.
34. Englund A., Freeman T. P., Murray R. M., McGuire P. (2017). Can we make cannabis safer? Lancet Psychiatry 4, 643–648. 10.1016/S2215-0366(17)30075-5 [PubMed] [Cross Ref]
35. Espejo-Porras F., Fernandez-Ruiz J., Pertwee R. G., Mechoulam R., Garcia C. (2013). Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacology 75, 155–163. 10.1016/j.neuropharm.2013.07.024 [PubMed] [Cross Ref]
36. Esposito G., Scuderi C., Savani C., Steardo L., Jr., De Filippis D., Cottone P., et al. . (2007). Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br. J. Pharmacol. 151, 1272–1279. 10.1038/sj.bjp.0707337 [PMC free article][PubMed] [Cross Ref]
37. Esposito G., Scuderi C., Valenza M., Togna G. I., Latina V., De Filippis D., et al. . (2011). Cannabidiol reduces Abeta-induced neuroinflammation and promotes hippocampal neurogenesis through PPARgamma involvement. PLoS ONE 6:e28668. 10.1371/journal.pone.0028668 [PMC free article] [PubMed] [Cross Ref]
38. Fagherazzi E. V., Garcia V. A., Maurmann N., Bervanger T., Halmenschlager L. H., Busato S. B., et al. . (2012). Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders. Psychopharmacology 219, 1133–1140. 10.1007/s00213-011-2449-3 [PubMed] [Cross Ref]
39. Farooqui T., Farooqui A. A. (2011). Lipid-mediated oxidative stress and inflammation in the pathogenesis of Parkinson’s disease. Parkinsons. Dis. 2011:247467. 10.4061/2011/247467 [PMC free article] [PubMed] [Cross Ref]
40. Flachenecker P., Henze T., Zettl U. K. (2014). Spasticity in patients with multiple sclerosis–clinical characteristics, treatment and quality of life. Acta Neurol. Scand. 129, 154–162. 10.1111/ane.12202[PubMed] [Cross Ref]
41. Garcia C., Palomo-Garo C., Garcia-Arencibia M., Ramos J., Pertwee R., Fernandez-Ruiz J. (2011). Symptom-relieving and neuroprotective effects of the phytocannabinoid Delta(9)-THCV in animal models of Parkinson’s disease. Br. J. Pharmacol. 163, 1495–1506. 10.1111/j.1476-5381.2011.01278.x [PMC free article] [PubMed] [Cross Ref]
42. García-Arencibia M., Gonzalez S., de Lago E., Ramos J. A., Mechoulam R., Fernandez-Ruiz J. (2007). Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res.1134, 162–170. 10.1016/j.brainres.2006.11.063 [PubMed] [Cross Ref]
43. Giacoppo S., Bramanti P., Mazzon E. (2017a). Sativex in the management of multiple sclerosis-related spasticity: an overview of the last decade of clinical evaluation. Mult. Scler. Relat. Disord.17, 22–31. 10.1016/j.msard.2017.06.015 [PubMed] [Cross Ref]
44. Giacoppo S., Pollastro F., Grassi G., Bramanti P., Mazzon E. (2017b). Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis. Fitoterapia116, 77–84. 10.1016/j.fitote.2016.11.010 [PubMed] [Cross Ref]
45. Gomes F. V., Del Bel E. A., Guimaraes F. S. (2013). Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 46, 43–47. 10.1016/j.pnpbp.2013.06.005 [PubMed][Cross Ref]
46. Gomes F. V., Llorente R., Del Bel E. A., Viveros M. P., Lopez-Gallardo M., Guimaraes F. S. (2015). Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol. Schizophr. Res. 164, 155–163. 10.1016/j.schres.2015.01.015 [PubMed] [Cross Ref]
47. Grlic L. (1976). A comparative study on some chemical and biological characteristics of various samples of cannabis resin. Bull. Narc. 14, 37–46.
48. Hampson A. J., Grimaldi M., Axelrod J., Wink D. (1998). Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. U.S.A. 95, 8268–8273. 10.1073/pnas.95.14.8268 [PMC free article] [PubMed] [Cross Ref]
49. Hassan S., Eldeeb K., Millns P. J., Bennett A. J., Alexander S. P., Kendall D. A. (2014). Cannabidiol enhances microglial phagocytosis via transient receptor potential (TRP) channel activation. Br. J. Pharmacol. 171, 2426–2439. 10.1111/bph.12615 [PMC free article] [PubMed] [Cross Ref]
50. Hayakawa K., Mishima K., Hazekawa M., Sano K., Irie K., Orito K., et al. . (2008). Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism. Brain Res. 1188, 157–164. 10.1016/j.brainres.2007.09.090 [PubMed] [Cross Ref]
51. Hecker M., Paap B. K., Goertsches R. H., Kandulski O., Fatum C., Koczan D., et al. . (2011). Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis. PLoS ONE 6:e29648. 10.1371/journal.pone.0029648 [PMC free article] [PubMed][Cross Ref]
52. Hind W. H., England T. J., O’Sullivan S. E. (2016). Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARgamma and 5-HT1A receptors. Br. J. Pharmacol. 173, 815–825. 10.1111/bph.13368 [PMC free article] [PubMed] [Cross Ref]
53. Hindocha C., Freeman T. P., Schafer G., Gardener C., Das R. K., Morgan C. J., et al. . (2015). Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur. Neuropsychopharmacol. 25, 325–334. 10.1016/j.euroneuro.2014.11.014 [PMC free article][PubMed] [Cross Ref]
54. Hodges A., Strand A. D., Aragaki A. K., Kuhn A., Sengstag T., Hughes G., et al. . (2006). Regional and cellular gene expression changes in human Huntington’s disease brain. Hum. Mol. Genet. 15, 965–977. 10.1093/hmg/ddl013 [PubMed] [Cross Ref]
55. Iffland K., Grotenhermen F. (2017). An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2, 139–154. 10.1089/can.2016.0034 [PMC free article] [PubMed] [Cross Ref]
56. Iuvone T., Esposito G., Esposito R., Santamaria R., Di Rosa M., Izzo A. A. (2004). Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J. Neurochem. 89, 134–141. 10.1111/j.1471-4159.2003.02327.x[PubMed] [Cross Ref]
57. Jacobs D. S., Kohut S. J., Jiang S., Nikas S. P., Makriyannis A., Bergman J. (2016). Acute and chronic effects of cannabidiol on Delta(9)-tetrahydrocannabinol (Delta(9)-THC)-induced disruption in stop signal task performance. Exp. Clin. Psychopharmacol. 24, 320–330. 10.1037/pha0000081 [PMC free article] [PubMed] [Cross Ref]
58. Jankovic J. (2005). Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord 20 (Suppl. 11), S11–S16. 10.1002/mds.20458 [PubMed] [Cross Ref]
59. Juknat A., Rimmerman N., Levy R., Vogel Z., Kozela E. (2012). Cannabidiol affects the expression of genes involved in zinc homeostasis in BV-2 microglial cells. Neurochem. Int. 61, 923–930. 10.1016/j.neuint.2011.12.002 [PubMed] [Cross Ref]
60. Kaplan J. S., Stella N., Catterall W. A., Westenbroek R. E. (2017). Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proc. Natl. Acad. Sci. U.S.A. 114, 11229–11234. 10.1073/pnas.1711351114 [PMC free article] [PubMed] [Cross Ref]
61. Klockgether T. (2004). Parkinson’s disease: clinical aspects. Cell Tissue Res. 318, 115–120. 10.1007/s00441-004-0975-6 [PubMed] [Cross Ref]
62. Kozela E., Pietr M., Juknat A., Rimmerman N., Levy R., Vogel Z. (2010). Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. J. Biol. Chem. 285, 1616–1626. 10.1074/jbc.M109.069294 [PMC free article] [PubMed] [Cross Ref]
63. Laprairie R., Bagher A., Kelly M., Denovan-Wright E. (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br. J. Pharmacol. 172, 4790–4805. 10.1111/bph.13250 [PMC free article] [PubMed] [Cross Ref]
64. Lastres-Becker I., Hansen H. H., Berrendero F., De Miguel R., Perez-Rosado A., Manzanares J., et al. . (2002). Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington’s disease. Synapse 44, 23–35. 10.1002/syn.10054[PubMed] [Cross Ref]
65. Lastres-Becker I., Molina-Holgado F., Ramos J. A., Mechoulam R., Fernandez-Ruiz J. (2005). Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease. Neurobiol. Dis. 19, 96–107. 10.1016/j.nbd.2004.11.009 [PubMed][Cross Ref]
66. Laun A. S., Song Z. H. (2017). GPR3 and GPR6, novel molecular targets for cannabidiol. Biochem. Biophys. Res. Commun. 490, 17–21. 10.1016/j.bbrc.2017.05.165 [PubMed] [Cross Ref]
67. Lee J. L. C., Bertoglio L. J., Guimaraes F. S., Stevenson C. W. (2017). Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. Br. J. Pharmacol. 174, 3242–3256. 10.1111/bph.13724 [PMC free article] [PubMed][Cross Ref]
68. Lerner P. P., Miodownik C., Lerner V. (2015). Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin. Neurosci. 69, 321–334. 10.1111/pcn.12270[PubMed] [Cross Ref]
69. Leweke F. M., Piomelli D., Pahlisch F., Muhl D., Gerth C. W., Hoyer C., et al. . (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry 2:e94. 10.1038/tp.2012.15 [PMC free article] [PubMed] [Cross Ref]
70. Long L. E., Malone D. T., Taylor D. A. (2006). Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 31, 795–803. 10.1038/sj.npp.1300838[PubMed] [Cross Ref]
71. López-Sendón Moreno J. L., Garcia Caldentey J., Trigo Cubillo P., Ruiz Romero C., Garcia Ribas G., Alonso Arias M. A., et al. . (2016). A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease. J. Neurol. 263, 1390–1400. 10.1007/s00415-016-8145-9 [PubMed] [Cross Ref]
72. MacDonald M. E., Barnes G., Srinidhi J., Duyao M. P., Ambrose C. M., Myers R. H., et al. (1993). Gametic but not somatic instability of CAG repeat length in Huntington’s disease. J. Med. Genet. 30, 982–986. 10.1136/jmg.30.12.982 [PMC free article] [PubMed] [Cross Ref]
73. Martínez-Pinilla E., Varani K., Reyes-Resina I., Angelats E., Vincenzi F., Ferreiro-Vera C., et al. . (2017). Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors. Front. Pharmacol. 8:744. 10.3389/fphar.2017.00744 [Cross Ref]
74. Martín-Moreno A. M., Reigada D., Ramirez B. G., Mechoulam R., Innamorato N., Cuadrado A., et al. . (2011). Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer’s disease. Mol. Pharmacol. 79, 964–973. 10.1124/mol.111.071290 [PMC free article] [PubMed] [Cross Ref]
75. Mason S. L., Barker R. A. (2016). Advancing pharmacotherapy for treating Huntington’s disease: a review of the existing literature. Expert Opin. Pharmacother. 17, 41–52. 10.1517/14656566.2016.1109630 [PubMed] [Cross Ref]
76. McColgan P., Tabrizi S. J. (2018). Huntington’s disease: a clinical review. Eur. J. Neurol. 25, 24–34. 10.1111/ene.13413 [PubMed] [Cross Ref]
77. McGuire P., Robson P., Cubala W. J., Vasile D., Morrison P. D., Barron R., et al. . (2018). Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am. J. Psychiatry 175, 225–231. 10.1176/appi.ajp.2017.17030325 [PubMed] [Cross Ref]
78. Mecha M., Torrao A. S., Mestre L., Carrillo-Salinas F. J., Mechoulam R., Guaza C. (2012). Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress. Cell Death Dis. 3:e331. 10.1038/cddis.2012.71 [PMC free article] [PubMed] [Cross Ref]
79. Mechoulam R., Shvo Y. (1963). Hashish—I: the structure of cannabidiol. Tetrahedron 19, 2073–2078. 10.1016/0040-4020(63)85022-X [PubMed] [Cross Ref]
80. Meredith G. E., Totterdell S., Potashkin J. A., Surmeier D. J. (2008). Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat. Disord. 14(Suppl. 2), S112–115. 10.1016/j.parkreldis.2008.04.012 [PMC free article] [PubMed] [Cross Ref]
81. Molderings G. J., Bonisch H., Hammermann R., Gothert M., Bruss M. (2002). Noradrenaline release-inhibiting receptors on PC12 cells devoid of alpha(2(-)) and CB(1) receptors: similarities to presynaptic imidazoline and edg receptors. Neurochem. Int. 40, 157–167. 10.1016/S0197-0186(01)00076-6 [PubMed] [Cross Ref]
82. Morales P., Isawi I., Reggio P. H. (2018). Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12. Drug Metab. Rev. 50, 74–93. 10.1080/03602532.2018.1428616 [PubMed] [Cross Ref]
83. Morales P., Reggio P. H. (2017). An update on non-CB1, non-CB2 cannabinoid related g-protein-coupled receptors. Cannabis Cannabinoid Res. 2, 265–273. 10.1089/can.2017.0036 [PMC free article] [PubMed] [Cross Ref]
84. Murphy M., Mills S., Winstone J., Leishman E., Wager-Miller J., Bradshaw H., et al. (2017). Chronic adolescent delta(9)-tetrahydrocannabinol treatment of male mice leads to long-term cognitive and behavioral dysfunction, which are prevented by concurrent cannabidiol treatment. Cannabis Cannabinoid Res. 2, 235–246. 10.1089/can.2017.0034 [PMC free article] [PubMed][Cross Ref]
85. Myers A. M., Siegele P. B., Foss J. D., Tuma R. F., Ward S. J. (2018). Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice. Br. J. Pharmacol. [Epub ahead of print]. 10.1111/bph.14147 [PubMed] [Cross Ref]
86. Nielsen S., Germanos R., Weier M., Pollard J., Degenhardt L., Hall W., et al. . (2018). The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Curr. Neurol. Neurosci. Rep. 18:8. 10.1007/s11910-018-0814-x [PubMed] [Cross Ref]
87. Niranjan R. (2014). The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson’s disease: focus on astrocytes. Mol. Neurobiol. 49, 28–38. 10.1007/s12035-013-8483-x[PubMed] [Cross Ref]
88. Oeckl P., Ferger B. (2016). Increased susceptibility of G-protein coupled receptor 6 deficient mice to MPTP neurotoxicity. Neuroscience 337, 218–223. 10.1016/j.neuroscience.2016.09.021 [PubMed][Cross Ref]
89. Oeckl P., Hengerer B., Ferger B. (2014). G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson’s disease. Exp. Neurol. 257, 1–9. 10.1016/j.expneurol.2014.04.010 [PubMed] [Cross Ref]
90. Osborne A. L., Solowij N., Weston-Green K. (2017). A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia. Neurosci. Biobehav. Rev. 72, 310–324. 10.1016/j.neubiorev.2016.11.012 [PubMed] [Cross Ref]
91. O’Sullivan S. E., Sun Y., Bennett A. J., Randall M. D., Kendall D. A. (2009). Time-dependent vascular actions of cannabidiol in the rat aorta. Eur. J. Pharmacol. 612, 61–68. 10.1016/j.ejphar.2009.03.010 [PubMed] [Cross Ref]
92. Pan H., Mukhopadhyay P., Rajesh M., Patel V., Mukhopadhyay B., Gao B., et al. . (2009). Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J. Pharmacol. Exp. Ther. 328, 708–714. 10.1124/jpet.108.147181 [PMC free article] [PubMed] [Cross Ref]
93. Patti F., Messina S., Solaro C., Amato M. P., Bergamaschi R., Bonavita S., et al. . (2016). Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J. Neurol. Neurosurg. Psychiatry 87, 944–951. 10.1136/jnnp-2015-312591 [PMC free article] [PubMed] [Cross Ref]
94. Pazos M. R., Mohammed N., Lafuente H., Santos M., Martinez-Pinilla E., Moreno E., et al. . (2013). Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors. Neuropharmacology 71, 282–291. 10.1016/j.neuropharm.2013.03.027 [PubMed][Cross Ref]
95. Pedrazzi J. F., Issy A. C., Gomes F. V., Guimaraes F. S., Del-Bel E. A. (2015). Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine. Psychopharmacology 232, 3057–3065. 10.1007/s00213-015-3945-7 [PubMed] [Cross Ref]
96. Peres F. F., Levin R., Suiama M. A., Diana M. C., Gouvea D. A., Almeida V., et al. . (2016). Cannabidiol prevents motor and cognitive impairments induced by reserpine in rats. Front. Pharmacol. 7:343. 10.3389/fphar.2016.00343 [PMC free article] [PubMed] [Cross Ref]
97. Perez-Reyes M., Timmons M. C., Davis K. H., Wall E. M. (1973). A comparison of the pharmacological activity in man of intravenously administered delta9-tetrahydrocannabinol, cannabinol, and cannabidiol. Experientia 29, 1368–1369. 10.1007/BF01922823 [PubMed][Cross Ref]
98. Pertwee R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br. J. Pharmacol. 153, 199–215. 10.1038/sj.bjp.0707442 [PMC free article] [PubMed] [Cross Ref]
99. Pertwee R. G., Ross R. A. (2002). Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fatty Acids 66, 101–121. 10.1054/plef.2001.0341 [PubMed] [Cross Ref]
100. Rajan T. S., Giacoppo S., Iori R., De Nicola G. R., Grassi G., Pollastro F., et al. . (2016). Anti-inflammatory and antioxidant effects of a combination of cannabidiol and moringin in LPS-stimulated macrophages. Fitoterapia 112, 104–115. 10.1016/j.fitote.2016.05.008 [PubMed][Cross Ref]
101. Rekand T. (2014). THC:CBD spray and MS spasticity symptoms: data from latest studies. Eur. Neurol. 71(Suppl. 1), 4–9. 10.1159/000357742 [PubMed] [Cross Ref]
102. Richter A., Loscher W. (2002). Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia. Eur. J. Pharmacol. 454, 145–151. 10.1016/S0014-2999(02)02477-9 [PubMed] [Cross Ref]
103. Rock E. M., Bolognini D., Limebeer C. L., Cascio M. G., Anavi-Goffer S., Fletcher P. J., et al. . (2012). Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br. J. Pharmacol. 165, 2620–2634. 10.1111/j.1476-5381.2011.01621.x [PMC free article][PubMed] [Cross Ref]
104. Ross R. A. (2003). Anandamide and vanilloid TRPV1 receptors. Br. J. Pharmacol. 140, 790–801. 10.1038/sj.bjp.0705467 [PMC free article] [PubMed] [Cross Ref]
105. Ross R. A. (2009). The enigmatic pharmacology of GPR55. Trends Pharmacol. Sci. 30, 156–163. 10.1016/j.tips.2008.12.004 [PubMed] [Cross Ref]
106. Russo E. B., Burnett A., Hall B., Parker K. K. (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem. Res. 30, 1037–1043. 10.1007/s11064-005-6978-1 [PubMed] [Cross Ref]
107. Russo E., Guy G. W. (2006). A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med. Hypotheses 66, 234–246. 10.1016/j.mehy.2005.08.026[PubMed] [Cross Ref]
108. Russo M., De Luca R., Torrisi M., Rifici C., Sessa E., Bramanti P., et al. . (2016). Should we care about sativex-induced neurobehavioral effects? A 6-month follow-up study. Eur. Rev. Med. Pharmacol. Sci. 20, 3127–3133. [PubMed]
109. Ryberg E., Larsson N., Sjogren S., Hjorth S., Hermansson N. O., Leonova J., et al. . (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152, 1092–1101. 10.1038/sj.bjp.0707460 [PMC free article] [PubMed] [Cross Ref]
110. Saft C., von Hein S. M., Lücke T., Thiels C., Peball M., Djamshidian A., et al. . (2018). Cannabinoids for treatment of dystonia in Huntington’s disease. J. Huntingtons Dis. [Epub ahead of print]. 10.3233/JHD-170283 [PubMed] [Cross Ref]
111. Sagredo O., Pazos M. R., Satta V., Ramos J. A., Pertwee R. G., Fernandez-Ruiz J. (2011). Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease. J. Neurosci. Res. 89, 1509–1518. 10.1002/jnr.22682 [PubMed] [Cross Ref]
112. Sagredo O., Ramos J. A., Decio A., Mechoulam R., Fernandez-Ruiz J. (2007). Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur. J. Neurosci. 26, 843–851. 10.1111/j.1460-9568.2007.05717.x [PubMed] [Cross Ref]
113. Sánchez-López F., Tasset I., Aguera E., Feijoo M., Fernandez-Bolanos R., Sanchez F. M., et al. . (2012). Oxidative stress and inflammation biomarkers in the blood of patients with Huntington’s disease. Neurol. Res. 34, 721–724. 10.1179/1743132812Y.0000000073 [PubMed] [Cross Ref]
114. Sandyk R., Snider S. R., Consroe P., Elias S. M. (1986). Cannabidiol in dystonic movement disorders. Psychiatry Res. 18:291. 10.1016/0165-1781(86)90117-4 [PubMed] [Cross Ref]
115. Santos N. A., Martins N. M., Sisti F. M., Fernandes L. S., Ferreira R. S., Queiroz R. H., et al. . (2015). The neuroprotection of cannabidiol against MPP(+)-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson’s disease. Toxicol. In Vitro 30(1 Pt B), 231–240. 10.1016/j.tiv.2015.11.004 [PubMed][Cross Ref]
116. Sartim A. G., Guimaraes F. S., Joca S. R. (2016). Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-Possible involvement of 5-HT1A and CB1 receptors. Behav. Brain Res. 303, 218–227. 10.1016/j.bbr.2016.01.033 [PubMed] [Cross Ref]
117. Schapira A. H., Cooper J. M., Dexter D., Clark J. B., Jenner P., Marsden C. D. (1990). Mitochondrial complex I deficiency in Parkinson’s disease. J. Neurochem. 54, 823–827. 10.1111/j.1471-4159.1990.tb02325.x [PubMed] [Cross Ref]
118. Schiavon A. P., Soares L. M., Bonato J. M., Milani H., Guimaraes F. S., Weffort de Oliveira R. M. (2014). Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice. Neurotox. Res. 26, 307–316. 10.1007/s12640-014-9457-0 [PubMed] [Cross Ref]
119. Schrag A., Horsfall L., Walters K., Noyce A., Petersen I. (2015). Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol. 14, 57–64. 10.1016/S1474-4422(14)70287-X [PubMed] [Cross Ref]
120. Sonego A. B., Gomes F. V., Del Bel E. A., Guimaraes F. S. (2016). Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice. Behav. Brain Res. 309, 22–28. 10.1016/j.bbr.2016.04.042 [PubMed] [Cross Ref]
121. Stern C. A. J., da Silva T. R., Raymundi A. M., de Souza C. P., Hiroaki-Sato V. A., Kato L., et al. . (2017). Cannabidiol disrupts the consolidation of specific and generalized fear memories via dorsal hippocampus CB1 and CB2 receptors. Neuropharmacology 125, 220–230. 10.1016/j.neuropharm.2017.07.024 [Cross Ref]
122. Tysnes O. B., Storstein A. (2017). Epidemiology of Parkinson’s disease. J. Neural Transm. 124, 901–905. 10.1007/s00702-017-1686-y [PubMed] [Cross Ref]
123. Valdeolivas S., Sagredo O., Delgado M., Pozo M. A., Fernandez-Ruiz J. (2017). Effects of a sativex-like combination of phytocannabinoids on disease progression in R6/2 mice, an experimental model of Huntington’s disease. Int. J. Mol. Sci. 18:E684. 10.3390/ijms18040684 [PMC free article][PubMed] [Cross Ref]
124. Valdeolivas S., Satta V., Pertwee R. G., Fernandez-Ruiz J., Sagredo O. (2012). Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB1 and CB2 receptors. ACS Chem. Neurosci. 3, 400–406. 10.1021/cn200114w [PMC free article] [PubMed] [Cross Ref]
125. Valvassori S. S., Bavaresco D. V., Scaini G., Varela R. B., Streck E. L., Chagas M. H., et al. . (2013). Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain. Rev. Bras. Psiquiatr. 35, 380–386. 10.1590/1516-4446-2012-0886[PubMed] [Cross Ref]
126. Watzl B., Scuderi P., Watson R. R. (1991). Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro, in Drugs of Abuse, Immunity, and Immunodeficiency, eds Friedman H., Klein T. W., Specter S., editors. (Boston, MA: Springer; ), 63–70. [PubMed]
127. Weiss L., Zeira M., Reich S., Har-Noy M., Mechoulam R., Slavin S., et al. . (2006). Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 39, 143–151. 10.1080/08916930500356674 [PubMed] [Cross Ref]
128. Wright M. J., Jr., Vandewater S. A., Taffe M. A. (2013). Cannabidiol attenuates deficits of visuospatial associative memory induced by Delta(9) tetrahydrocannabinol. Br. J. Pharmacol. 170, 1365–1373. 10.1111/bph.12199 [PMC free article] [PubMed] [Cross Ref]
129. Zhang X. Y., Tan Y. L., Zhou D. F., Cao L. Y., Wu G. Y., Haile C. N., et al. . (2007). Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. J. Clin. Psychiatry 68, 754–760. 10.4088/JCP.v68n0513 [PubMed] [Cross Ref]
130. Zuardi A. W. (2008). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev. Bras. Psiquiatr. 30, 271–280. 10.1590/S1516-44462008000300015 [PubMed][Cross Ref]
131. Zuardi A. W., Crippa J. A., Hallak J. E., Pinto J. P., Chagas M. H., Rodrigues G. G., et al. . (2009). Cannabidiol for the treatment of psychosis in Parkinson’s disease. J. Psychopharmacol. 23, 979–983. 10.1177/0269881108096519 [PubMed] [Cross Ref]

[/et_pb_accordion_item][et_pb_accordion_item _builder_version=”3.10″ title=”Close Accordion” use_background_color_gradient=”off” background_color_gradient_start=”#2b87da” background_color_gradient_end=”#29c4a9″ background_color_gradient_type=”linear” background_color_gradient_direction=”180deg” background_color_gradient_direction_radial=”center” background_color_gradient_start_position=”0%” background_color_gradient_end_position=”100%” background_color_gradient_overlays_image=”off” parallax=”off” parallax_method=”on” background_size=”cover” background_position=”center” background_repeat=”no-repeat” background_blend=”normal” allow_player_pause=”off” background_video_pause_outside_viewport=”on” open_toggle_background_color=”#ffffff” closed_toggle_background_color=”#ffffff” text_shadow_style=”none” custom_padding=”0px|||” custom_padding_tablet=”0px|||” custom_padding_phone=”0px|||” box_shadow_style=”none” custom_css_main_element=”border:none;” custom_css_toggle_title=”font-size:0.8em;” custom_css_toggle_icon=”display:none;” /][/et_pb_accordion][/et_pb_column][/et_pb_row][/et_pb_section]